Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Holdings Cut by GSA Capital Partners LLP

GSA Capital Partners LLP reduced its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 25.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,459 shares of the company’s stock after selling 13,664 shares during the quarter. GSA Capital Partners LLP’s holdings in Mirum Pharmaceuticals were worth $1,823,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Federated Hermes Inc. increased its holdings in shares of Mirum Pharmaceuticals by 9,440.4% in the first quarter. Federated Hermes Inc. now owns 347,366 shares of the company’s stock valued at $15,649,000 after buying an additional 343,725 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Mirum Pharmaceuticals by 46.7% in the fourth quarter. Nuveen Asset Management LLC now owns 722,155 shares of the company’s stock valued at $29,861,000 after buying an additional 229,746 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at $6,507,000. Marshall Wace LLP increased its holdings in shares of Mirum Pharmaceuticals by 641.6% in the fourth quarter. Marshall Wace LLP now owns 175,913 shares of the company’s stock valued at $7,274,000 after buying an additional 152,191 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Mirum Pharmaceuticals by 10.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company’s stock valued at $58,831,000 after buying an additional 138,623 shares in the last quarter.

Mirum Pharmaceuticals Trading Down 0.7%

NASDAQ MIRM opened at $51.49 on Tuesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.20 and a twelve month high of $54.78. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -31.98 and a beta of 0.97. The firm’s 50 day moving average price is $49.15 and its two-hundred day moving average price is $46.71.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The business had revenue of $111.59 million for the quarter, compared to analysts’ expectations of $98.47 million. During the same period in the previous year, the company posted ($0.54) EPS. Mirum Pharmaceuticals’s revenue was up 61.2% on a year-over-year basis. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 564 shares of the business’s stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $48.25, for a total transaction of $27,213.00. Following the transaction, the senior vice president directly owned 2,903 shares in the company, valued at $140,069.75. The trade was a 16.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 14.36% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MIRM. Wall Street Zen cut Mirum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 6th. JMP Securities upped their price target on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a “market outperform” rating in a report on Friday, May 9th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. HC Wainwright reiterated a “buy” rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Finally, Evercore ISI reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, July 11th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $65.50.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.